Attention Deficit Hyperactivity Disorder (ADHD) is a neurobehavioral disorder characterized by inattention and hyperactivity, and associated with difficulties in academic, family, and social settings. Onset is usually in childhood, and it affects over 5.4 million children between ages 4 and 17 (nearly 1 in 10 children). Symptoms include difficulties with paying attention, being easily distracted, disorganized work habits, forgetfulness in daily activities, fidgeting, restlessness, trouble taking turns, and making careless mistakes in school or other activities.

Evidence-based treatments are available (see the AACAP Practice Parameters, for example), but no treatment works for everyone, and concerns about side effects worry many patients and their families. A wider set of safe and effective therapeutic options appears necessary.

Trigeminal Nerve Stimulation (TNS) is a new investigational treatment for disorders of the brain, including treatment-resistant epilepsy, major depression, PTSD, and now ADHD. TNS for neurological and psychiatric disorders was invented by Drs. Christopher M. DeGiorgio, Ian A. Cook, and their teams at UCLA; the intellectual property is owned by the University of California and has been licensed to a neuromodulation company, NeuroSigma, Inc. for further translational development into treatments that can be made available to patients.

For a video perspective on TNS, you can view this video on YouTube of Dr. Christopher DeGiorgio, one of the inventors of TNS, talking about its first use in epilepsy.

NPR interview with a patient using TNS for epilepsy (July 27, 2011)